Schizophrenia Drugs Market - Growth, Trends, and Forecast (2019-2024)

The Schizophrenia Drugs market is segmented on the basis of Therapeutic Class (Second-generation Antipsychotics and Third-generation Antipsychotics), Treatment, and Geography.

Market Snapshot

Schizophrenia Drugs Market_1
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

2.8%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Schizophrenia is a mental disorder that is characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Although the course of schizophrenia varies among individuals, it is typically persistent and can be both severe and disabling. It is typically diagnosed in the late years of teenage or the early thirties, and tends to emerge earlier in males (late adolescence – early twenties) than females (early twenties – early thirties). Subtle changes in cognition and social relationships are expected to precede the actual diagnosis, often by years. Findings from the global burden of the disease study in 2016 indicated that population growth and aging led to an increasing disease burden, which can be attributed to schizophrenia, globally, especially in the middle-income countries. Globally, an estimated 21 million people are suffering from schizophrenia. Furthermore, this number is likely to continue to increase, along with the growth in ageing population. Canada has a high prevalence of schizophrenia, which can be attributed to three possible factors. Firstly, many studies established that immigrants have incidence of schizophrenia in both the first and second generations. Canada has a high rate of immigration, about twice that of the United States. Moreover, 20% of the Canadians were born in another country. Secondly, schizophrenia is common in countries at high latitude, although the cause of this effect is unknown. Thirdly, urban population is witnessing high prevalence of schizophrenia, and 80% of the Canadians live in cities.

Hence, the rise in incidence of the disease and the increasing need to manage it effectively is driving the growth of the market studied.

 

Scope of the Report

Schizophrenia is characterized by delusions, hallucinations, and other cognitive difficulties, which can often be a lifelong struggle. It is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may seem like they have lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be disabling.

By Therapeutic Class
Second-generation Antipsychotics
Third-generation Antipsychotics
Other Therapeutic Classes
By Treatment
Oral
Injectables
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Second-generation Antipsychotics Sub-segment is Expected to record the Highest CAGR over the Forecast Period

Schizophrenia is a serious mental illness, which for some people can become a long term problem. The usual first-line treatment for schizophrenia is antipsychotic medication. One of the commonly preferred medications is risperidone, which is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior. It is expected to help in curing some or all of the symptoms of schizophrenia. Moreover, it is FDA approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of the bipolar disorder (Risperdal Consta® only), and irritability associated with autistic disorders. In cases where patients do not respond well to these medications, high doses are often used. This can cause adverse effects and set up a cycle where individuals gain some benefits from the medication, develop side effects, then stop taking it and relapse. Therefore, it would be helpful to find the optimum dose of each antipsychotic for different groups of people. There are several second-generation drugs available in the market, which are commonly proposed by the doctors/physicians. Therefore, considering the aforementioned reasons, the market for second-generation antipsychotics is likely to grow steadily over the forecast period.

Schizophrenia Drugs Market_2

To understand key trends, Download Sample Report

The North American is expected to Dominate the Market over the Forecast Period

The North American region is expected to dominate the market studied over the forecast period. In the North American region, the United States accounted for the largest market share, as a major section of the population is approaching such medications therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care, for early treatment capabilities, along with involvement of government in increasing healthcare expenditure. This is driving the growth of the market studied.

schizophrenia drugs market image 3

To understand geography trends, Download Sample Report

Competitive Landscape

The Schizophrenia Drugs market is competitive and consists of major and small players. In terms of market share, the major players currently dominate the market. Some of the major market players include Alkermes Plc, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, and Allergan Plc, among others.

Major Players

  1. Alkermes Plc
  2. Bristol-Myers Squibb
  3. Eli Lilly and Company
  4. Johnson & Johnson
  5. Allergan Plc

* Complete list of players covered available in the table of contents below

Schizophrenia Drugs Market_4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Schizophrenia and Associated Disorders

      2. 4.2.2 Increase in Focus of Governments and Health Care Organizations on Mental Health

      3. 4.2.3 Increasing Investments in R&D

    3. 4.3 Market Restraints

      1. 4.3.1 Increase in Cases of Addiction Associated with these Drugs

      2. 4.3.2 Patent Expiry of Major Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapeutic Class

      1. 5.1.1 Second-generation Antipsychotics

      2. 5.1.2 Third-generation Antipsychotics

      3. 5.1.3 Other Therapeutic Classes

    2. 5.2 By Treatment

      1. 5.2.1 Oral

      2. 5.2.2 Injectables

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alkermes Plc

      2. 6.1.2 Allergan Plc

      3. 6.1.3 AstraZeneca

      4. 6.1.4 Bristol-Myers Squibb

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sumitomo Dainippon Pharma

      9. 6.1.9 Vanda Pharmaceuticals

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information